Together, these data suggest that the combination of dual PI3K/mTOR and a BCL-2/BCL-XL inhibitor significantly enhances the induction of apoptosis in DLBCL cell lines relative to single agent treatment. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.